Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04667026
Recruiting Observational

Observational Study on Patients With HIV/AIDS(OSPWH)

NCT04667026 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou 8th People's Hospital
Phase
Observational
Started
2009-01-01
Last updated
2022-09-14

Condition(s) studied

HIV Infections

Study summary

To establish a follow-up cohort of antiretroviral therapy(ART) for patients with HIV/AIDS, to observe the ART efficacy and adverse reactions, complications in the process of ART, as well as mortality and causes of death, so as to provide basis for further improving ART efficacy and quality of life of the patients.

Eligibility

Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients has a history of diagnosis of HIV. * Receiving antiretroviral therapy. * Good treatment compliance. Exclusion Criteria: * Aged less than 14 years of old.

Primary outcome measure(s)

  • The rate of virological suppression after antiretroviral therapy. — Year 10
    After ART, HIV RNA level in plasma were quantified every year. The rate of HIV-RNA\<400 copies/ml will be used to evaluate the efficacy of ART and the variation tendency of the rate of virological suppression will be described.

Trial sites (1)

FacilityCityRegionStatus
Guangzhou Eighth People's Hospital Guangzhou Guangdong Recruiting

More Guangzhou 8th People's Hospital trials in China

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads Recruiting
Simplified Treatment of Anti-retrovirus in China (C-STAR) Recruiting
Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock Recruiting
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function Recruiting
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia Recruiting

Other trials for the same condition

Gut and Vaginal Microbiota Profile Study for HIV Women Recruiting
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04667026 on ClinicalTrials.gov ↗ ← All trials in China